Se­lec­ta Bio­sciences is nar­row­ing its fo­cus

Se­lec­ta Bio­sciences an­nounced Thurs­day that it will stop in­vest­ment in most of its pipeline as­sets ex­cept for a treat­ment for chron­ic re­frac­to­ry gout li­censed to Swedish phar­ma So­bi and a gene ther­a­py it’s de­vel­op­ing with Astel­las.

The com­pa­ny plans to sub­mit a BLA for SEL-212 in the first half of next year.

“While we firm­ly be­lieve that the bal­ance of our pipeline be­yond SEL-212 has the po­ten­tial to gen­er­ate mean­ing­ful re­turns for stock­hold­ers, we rec­og­nize that sig­nif­i­cant cap­i­tal and time will be re­quired to ad­vance these as­sets to val­ue cre­at­ing in­flec­tion points on our own. And as such, we have tak­en the de­ci­sion to sus­pend fur­ther in­vest­ments in all pro­grams be­yond SEL-212,” Se­lec­ta CEO Carsten Brunn said on an in­vestor call.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER